Modern WisdomHow Does The Cannabis Industry Work? - Chris Walsh | Modern Wisdom Podcast 333
CHAPTERS
- 0:00 – 1:41
Why an MBA ends up in cannabis: opportunity, impact, and building a new industry
Chris Walsh explains how he entered the cannabis space in 2011 while finishing his MBA, despite skepticism from others. He frames cannabis as both a massive business opportunity and a product category that can genuinely help people.
- •Entered cannabis in 2011 while completing an MBA; faced social/professional doubts
- •Journalism/business reporting background shaped his approach
- •Cannabis is now a global opportunity (US, Canada, Europe, South America)
- •Motivation includes both industry-building and perceived public benefit
- 1:41 – 5:37
Why cannabis is uniquely exciting (and why it’s still so hard)
Walsh describes the rapid shift from taboo to mainstream acceptance as a core source of intrigue. He also outlines why the industry is unusually difficult to understand and operate in, especially due to fragmented regulations and unconventional business norms.
- •Acceptance and normalization accelerated faster than expected
- •Early era had low barriers and ‘American dream’ accessibility
- •Regulatory fragmentation: state-by-state and city-by-city rules and jargon
- •Industry culture differs from typical corporate norms; trust networks matter
- 5:37 – 6:57
Early-day paranoia and the ‘are you FBI?’ moment
Walsh recounts how early cannabis professionals feared federal raids even while operating openly under state rules. A trade group bathroom conversation captures the climate of uncertainty and risk at the time.
- •Medical-only era in Colorado and limited legal states
- •Operators often came from legacy/illicit market backgrounds
- •Fear of federal enforcement was real and immediate
- •Industry meetings carried genuine risk of crackdowns
- 6:57 – 10:15
How state-legal but federally-illegal cannabis functions in practice
Walsh explains the uneasy equilibrium: federal illegality persists while enforcement was deprioritized, enabling state industries to grow. State regulation became key to public acceptance and to lowering federal enforcement pressure.
- •Federal government informally deprioritized enforcement rather than legalizing
- •Early crackdowns/raids created uncertainty for businesses
- •Obama-era guidance enabled growth, especially where states regulated tightly
- •Regulations professionalized the market and reduced public backlash
- 10:15 – 12:59
From memos to momentum: the industry becomes too big to ignore
The conversation covers how federal posture evolved slightly for adult-use and why a feared crackdown under Trump didn’t materialize. Walsh notes high public support and argues the US is paradoxically behind many countries on federal medical legalization.
- •Adult-use guidance extended similar ‘regulated = lower priority’ logic
- •Trump-era uncertainty (Jeff Sessions) but no major crackdown
- •Polling: very high support for medical; majority support for recreational
- •US leads in market size/innovation but lags many countries federally
- 12:59 – 14:50
What legalization could look like in the UK (and why change can come suddenly)
Walsh and Williamson discuss the UK’s cultural and political hesitation, alongside examples of how medical stories can rapidly shift policy. Walsh argues sudden inflection points are common in cannabis reform globally.
- •Europeans often predicted the UK would be ‘last’ to legalize
- •Medical cases (e.g., seizures/CBD) can catalyze public debate
- •Policy change can happen faster than expected despite cultural resistance
- •UK differs from places like Germany in public visibility of use
- 14:50 – 18:59
Losing the romance: counterculture vs corporate cannabis
They explore how partial illegality and legacy culture still create a ‘romance’ for some consumers. Walsh argues corporate normalization helped legalization but risks squeezing out smaller players and diluting what made the industry distinctive.
- •Some users miss the ‘Johnny Fat Bags’ informal sourcing experience
- •Corporate polish makes cannabis more acceptable to mainstream voters
- •Tension: normalization vs preserving culture and accessibility
- •Concern that corporatization blocks entrepreneurs without mainstream credentials
- 18:59 – 23:24
Celebrity brands, ex-politicians, and the race to build recognizable names
Williamson asks about the marketing ‘starter pistol’ after legalization, and Walsh explains celebrity endorsements as standard brand-building. He adds that the next wave includes former regulators and politicians joining cannabis company boards.
- •Celebrity branding used to stand out in crowded markets
- •Early celebrity wave tied to cannabis culture (e.g., Cheech & Chong)
- •New wave includes politicians/regulators for credibility and access
- •Normalization expands who is willing to attach their name to cannabis
- 23:24 – 27:46
Barriers to entry: still ‘easy’ vs tech, but getting expensive fast
Walsh clarifies that entry costs vary widely by state, but the overall trend is toward higher capitalization and stricter licensing. Even if production isn’t as complex as consumer electronics, compliance and licensing can require millions upfront.
- •US market remains fragmented; each state is effectively its own industry
- •Some states try to keep fees low and include social equity provisions
- •Trend: proving capital and operational capacity to win licenses
- •A ‘million or two’ may be needed in many states just to start
- 27:46 – 32:21
Dispensary experiences as retail theater: from Apple Stores to Vegas spectacles
They compare different dispensary models and why no single format is ‘best’ given diverse consumer segments. Stories from California and Las Vegas illustrate how retail ranges from earthy boutique vibes to extreme entertainment-driven showpieces.
- •Different customer archetypes want different retail aesthetics
- •MedMen as ‘Apple Store’ style vs earthy independent dispensaries
- •Vegas example (Planet 13): spectacle marketing and immersive design
- •Location and local culture heavily shape retail strategy
- 32:21 – 34:50
Market size and growth: the numbers (and why they’re hard to measure)
Walsh estimates US retail cannabis sales around $20B with strong year-on-year growth, noting measurement challenges because governments don’t track it uniformly. He compares cannabis to major industries like the NFL and craft beer to contextualize its scale.
- •US retail cannabis estimated around $20B; expected ~30% growth
- •Forecast: potentially doubling by mid-decade (2025/2026)
- •Data is difficult: inconsistent tracking and market fragmentation
- •Cannabis already rivals or surpasses major categories (NFL; approaching craft beer)
- 34:50 – 38:33
COVID’s unexpected boost: ‘essential business’ status and record sales
Walsh explains that while many regions paused reform efforts, US cannabis businesses largely stayed open as essential services. Lockdowns, stimulus money, and consumer experimentation drove record sales even in mature markets like Colorado.
- •Europe and other regions slowed legalization/program rollout
- •Many US states deemed medical (and often recreational) cannabis essential
- •Lockdowns + stimulus + limited spending outlets increased demand
- •Record sales occurred even in long-established markets
- 38:33 – 40:26
Medical vs recreational: why adult-use dominates and patients drop off
They discuss how recreational sales surpassed medical and now dwarf it. Walsh explains that once adult-use arrives, patients often stop renewing cards due to convenience and fewer administrative burdens.
- •Recreational surpassed medical around 2017 (per estimates)
- •Adult-use now several times larger than medical sales
- •Medical patient counts often decline after recreational legalization
- •Unclear whether future markets merge or maintain separate medical regimes
- 40:26 – 49:15
Hype, mismanagement, and how cannabis companies fail (plus a psychedelics detour)
Walsh avoids commenting on specific companies but describes systemic problems: overexpansion, shortcuts in legal gray areas, and poor governance—pointing to Canada’s early exuberance as a cautionary tale. The conversation then turns to psychedelics, where he sees interest and funding but uncertain market structure and questionable ‘cannabis-led’ crossover logic.
- •Industry has poor operators: overgrowth, weak financial discipline, bad decisions
- •Canada illustrates hype cycles and overinvestment after legalization
- •Failure recipe: chasing every opportunity, cutting corners, breaking trust, ignoring cannabis expertise
- •Psychedelics: rising investment and buzz, but unclear business model and appropriate leadership
- 49:15 – 51:50
Product innovation: from suppositories to mints, drinks, and water-soluble powders
They trade examples of surprising cannabis delivery formats and how product variety drives consumer adoption. Walsh notes ongoing experimentation across edibles, topicals, beverages, and niche wellness/sexual health products.
- •Unusual medical formats exist (e.g., suppositories)
- •Topicals and specialty wellness products broaden appeal beyond smoking
- •Microdosing formats like low-mg mints make use more ‘routine-friendly’
- •Innovation includes beverages and water-soluble powders for mixing into drinks
- 51:50 – 58:36
CBD’s future, research gaps, and basic risk framing (plus where to follow Walsh’s work)
Walsh discusses CBD’s global prominence, the lack of definitive science, and the likely emergence of other cannabinoids beyond CBD. They touch on cautious moderation, concerns about THC for developing brains, and close with where to find MJBizDaily and Walsh’s podcast.
- •CBD dominates headlines, but many cannabinoids remain underexplored
- •Many ‘medical cannabis’ programs globally are effectively low-THC/CBD-focused
- •Research is limited; consumer demand may persist or fade like other supplement fads
- •Resources: mjbizdaily.com, MJBizCon, and Walsh’s ‘Seed to CEO’ podcast
